Arcato closes seed round, reports positive Phase 1 results for opioid-sparing dental gel
What's the deal? Arcato LaboratoriesDealroom has a profile for this one. Try Dealroom → has closed its first, fully subscribed financing round, the company said on August 19, 2026. It announced the seed round alongside topline results from a first-in-human Phase 1 trial of its lead candidate, ARC-001 Gel.
What's the endgame? ARC-001 Gel is a single-dose, sustained-release formulation combining three non-addictive anesthetics — benzocaine, lidocaine, and bupivacaine. It is applied once, directly into the tooth socket after extraction, with no needle or injection, and is designed to relieve pain for up to seven days.
What did the trial show? The Phase 1 study, in patients recovering from third molar (wisdom tooth) surgery, met its primary safety endpoint, supporting further Phase 2/3 development. Exploratory analyses suggested pain reduction within the first 24 hours and possible relief for up to a week.
Notably, patients on placebo self-reported needing opioids twice as often as those given ARC-001 Gel.
Why now? More than 3 million patients a year undergo third molar surgery in the US, and demand for non-opioid pain options is rising. Arcato said it is aligned with the Food and Drug Administration's May 2026 draft guidance on developing non-opioid analgesics.
"Our clinical results demonstrate that ARC-001 Gel is an exciting new approach to managing oral pain," said Jeff Miller, chief executive officer of Arcato Laboratories.
What could go wrong? The efficacy findings are exploratory, not confirmatory, and safety was the trial's only primary endpoint. The candidate still faces Phase 2/3 development and regulatory review before reaching patients.
The signal: Arcato joins a wave of developers targeting post-surgical pain without opioids, a category regulators are now actively shaping. A needle-free, week-long option for a high-volume procedure like wisdom tooth removal points to where opioid-sparing care may head next.
Read more: PR Newswire
Image credit: Arcato Laboratories
